Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor

• Status: Recruiting
• Trial end date: 2025-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether perioperative intravenous administration of pantoprazole will improve kidney function parameters following cardiac surgery with cardiopulmonary bypass compared to famotidine and to determine whether perioperative intravenous administration of pantoprazole will decrease the incidence of postoperative Acte Kidney Injury (AKI) and major adverse kidney events (MAKE).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center, Houston
• Collaborator: Society of Cardiovascular Anesthesiologists
• Treatments: Famotidine; Pantoprazole

Criteria

Inclusion Criteria:

• Scheduled for elective cardiac surgery with cardio pulmonary bypass (CPB) with a high risk of developing AKI (Cleveland risk score equal or higher than 3, please see the appended table at end of the revised protocol)

Exclusion Criteria:

• Preoperative eGFR<30 ml/min per 1.73 m2

• Dialysis dependence

• Emergency surgery

• Interstitial nephritis

• Pregnancy

• Nursing Patients

• Proton pump inhibitors (PPIs) hypersensitivity

• Liver disease

• Vitamin B12 deficiency